Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Remainder of 2020

Total operating lease liabilities

Lease Agreements (Tables)

6 Months Ended

Jun. 30, 2020

For the three and six months ended June 30, 2020, the components of our operating lease expense were as follows (in thousands):


		Three Months Ended		Six Months Ended
		June 30,		June 30,
Fixed operating lease expense	$	1,340	$	2,680
Variable operating lease expense		216		467
Total operating lease expense	$	1,556	$	3,147

Supplemental information related to the Company’s operating lease for the three and six months ended June 30, 2020 were as follow (in thousands):


		Three Months Ended		Six Months Ended
		June 30,		June 30,
Cash payments included in the measurement of operating lease liabilities	$	2,432	$	4,832
Right-of-use asset obtained in exchange for operating lease obligations		—		—

The following table presents the future lease payments of our operating lease liabilities as of June 30, 2020 (in thousands):


Remainder of 2020	$	4,863
2021		10,082
2022		10,485
2023		877
Total operating lease payments		26,307
Less: imputed interest		(3,004)
Total operating lease liabilities	$	23,303

For the three and six months ended June 30, 2020, we have the following operating sublease information (in thousands):

The following table presents the future lease payments we expect to receive under our sublease as of June 30, 2020 (in thousands):